GlaxoSmithKline’s Pazopanib Shows Positive Results In Renal Cell Carcinoma
This article was originally published in The Pink Sheet Daily
Executive Summary
Preliminary analysis shows a 73 percent total disease control rate, according to presentation at ASCO.